Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Nerviano Medical Sciences
Woman and Man Max 99 years
Nerviano Medical Sciences S.r.l
Update Il y a 4 ans
An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression
To determine the anti-tumor activity of PHA-739358 in patients with Multiple Myeloma (MM) harbouring the t (4;14) translocation.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Nerviano Medical Sciences S.r.l
Update Il y a 4 ans
Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma
Evaluation of the survival rate at 7 months
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Nerviano Medical Sciences S.r.l
Update Il y a 4 ans
Phase II study of oral PHA-848125AC in patients with thymic carcinoma previously treated with chemotherapy
Assessment of the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy. Antitumor ac...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years and 75 years
Nerviano Medical Sciences
Update Il y a 4 ans
NERVIANO AURA-6202-011 : Essai de phase 2 évaluant l’efficacité du PHA-739358, chez des patients ayant un myélome multiple. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An exploratory phase II study of PHA-739358 in patients with multiple myeloma harbouring the t(4;14) translocation with or without FGFR3 expression
Country
France
organs
Myélomes
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Nerviano Medical Sciences S.r.l
Update Il y a 4 ans
Estudio Fase I/II de PHA-848125AC administrado diariamente por vía oral durante 14 días consecutivos cada tres semanas en pacientes con glioma maligno recurrente
Phase I part: - To determine the maximum tolerated dose (MTD) and the associated dose-limiting toxicities (DLTs) of PHA-848125AC administered orally once daily for 14 consecutive days followed by 7 da...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Nerviano Medical Sciences
Update Il y a 4 ans
NERVIANO CDKO-125a-006 : Essai de phase 2 évaluant l'efficacité du PHA-848125AC en traitement de 2ème ligne chez des patients ayant un carcinome thymique non opérable, en rechute ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Phase II study of oral PHA-848125AC in patients with thymic carcinoma previously treated with chemotherapy
Country
France
organs
Système endocrinien - autres
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information